Dr Reddy’s sued for patent infringement

BioMarin Pharmaceutical, a drugs company focusing on genetic diseases, has filed a complaint against Dr Reddy’s Laboratories for alleged patent infringement over the drug Kuvan (sapropterin dihydrochloride).

Kuvan is a treatment for patients with phenylketonuria, an inherited disorder that increases the levels of phenylalanine in the blood.

The claim, which was filed yesterday, February 6 in the US District Court for the District of New Jersey, arose after Dr Reddy’s filed an Abbreviated New Drug Application with the Food and Drug Administration.

Dr Reddy’s is seeking approval to market a generic version of Kuvan which would, according to BioMarin, infringe US patent numbers 7,566,714; 7,612,073; 8,067,416; RE43,797; 9,216,178; and 9,433,624.

BioMarin has asked the court for a ruling in its favour, as well as an injunction enjoining Dr Reddy’s from bringing the generic drug to market.

The company has also asked to be awarded attorneys’ fees, as well expenses for bringing the case to court.